Wybranowski Tomasz, Cyrankiewicz Michał, Ziomkowska Blanka, Kruszewski Stefan
Biophysics Department, Medical Physics Division, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Biosystems. 2008 Dec;94(3):258-62. doi: 10.1016/j.biosystems.2008.05.034. Epub 2008 Jul 31.
The determination of affinity of warfarin and flurbiprofen to human serum albumin (HSA) by fluorescence anisotropy measurements of carboxylate form of camptothecin (CPT-C) is the subject of this paper. A simple method based on measurements of fluorescence anisotropy of CPT-C allows to determine the affinity constant of CPT-C to HSA by computation of the fraction of bound CPT-C molecules with HSA It was observed, that adding of competing drug to plasma significant reduces the rate of increase of CPT-C fluorescence anisotropy with increase of albumin concentration and, the affinity constant of CPT-C to HSA decreases. The hypothesis of interactions between competing drug and CPT-C is presented. The results of these studies suggest that CPT-C displaces other drug from protein binding site and the degree of this displacement depends on concentration of drug and drug-HSA binding affinity. The presented in this paper biosystems research allows to estimate the affinity constant of warfarin and flurbiprofen. It was also confirmed that despite that most of drugs bind predominantly to Site I or Site II of HSA (only one of these sites is high-affinity site), at elevated concentrations, part of drug molecules can be bound to low-affinity site of HSA.
通过喜树碱羧酸盐形式(CPT-C)的荧光各向异性测量来测定华法林和氟比洛芬与人血清白蛋白(HSA)的亲和力是本文的主题。一种基于CPT-C荧光各向异性测量的简单方法,通过计算与HSA结合的CPT-C分子分数来确定CPT-C与HSA的亲和常数。观察到,向血浆中添加竞争性药物会显著降低CPT-C荧光各向异性随白蛋白浓度增加的增加速率,并且CPT-C与HSA的亲和常数降低。提出了竞争性药物与CPT-C之间相互作用的假设。这些研究结果表明,CPT-C从蛋白质结合位点取代了其他药物,这种取代程度取决于药物浓度和药物-HSA结合亲和力。本文所展示的生物系统研究能够估算华法林和氟比洛芬的亲和常数。还证实了,尽管大多数药物主要结合于HSA的位点I或位点II(这些位点中只有一个是高亲和力位点),但在高浓度下,部分药物分子可结合于HSA的低亲和力位点。